EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial

Masatoshi Jinnin iD, Toshio Shimokawa, Akiko Kishi, Nobukazu Hayashi, Michiko Nagahama, Akiharu Kubo iD, Michio Ozeki, Shuichi Shimada iD, Satoshi Fukushima, Tomotaka Kawabata, Tomoki Okuyama, Aki Okubo und 6 weitere

The Journal of Dermatology · 2025-05 · 52 (5) · 872-887

DOI: 10.1111/1346-8138.17688 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Dermatology, online erschienen am 05.03.2025. Verfasst von Masatoshi Jinnin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Sirolimus, Skin Neoplasms, Hemangioma, Vascular Malformations. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy, safety, and optimal concentration of topical sirolimus gel for treatment of cutaneous lesions of vascular anomalies requires evaluation. This study was a multicenter, double‐blind, placebo‐controlled, parallel‐group, phase II randomized clinical trial. We enrolled patients with venous malformation ( n = 27), lymphatic malformation ( n = 14), tufted angioma ( n = 8), or kaposiform hemangioendothelioma ( n = 1). Patients applied either placebo or 0.2% or 0.4% topical sirolimus gel to the target lesion twice per day for 12 weeks. The primary endpoint was the overall improvement score in the target lesion assessed from photographs by the independent review committee at Week 12. There was no statistically significant difference in the mean improvement score in the 0.2% group ( p = 0.410) or the 0.4% group ( p = 0.549) compared with in the placebo group. Thus, we could not prove the efficacy of topical sirolimus for cutaneous vascular anomalies in this protocol. Conversely, the improvement in target lesion size at Week 12 assessed by the committee as one of the 16 secondary endpoints was significantly higher in the 0.4% sirolimus gel group than in the placebo group ( p = 0.031). In the post‐hoc analysis outside the protocol tracing the contour of the lesion, the percentages of patients with ≥20% reduction in the lesion area increased dose‐dependently (0%, 37.5%, and 65.0% in the placebo, 0.2%, and 0.4% group, respectively). Regarding safety, irritation and dermatitis at the application site occurred in the 0.4% gel group. Sirolimus gel reduced lesion size in our cohort. The safety data demonstrated topical sirolimus to have an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusSkin NeoplasmsHemangiomaVascular MalformationsHemangioendotheliomaSarcoma, KaposiHumansMaleFemaleDouble-Blind MethodAdultTreatment OutcomeAdministration, CutaneousYoung AdultAdolescentMiddle AgedChildGelsKasabach-Merritt SyndromeSkin

Stichwörter der Autor:innen

lymphatic malformationsirolimusvascular anomaliesvascular tumorvenous malformation

Substanzen

SirolimusGels

Autor:innen und Institutionen

  • Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
  • Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama, Japan.
  • Department of Dermatology, Toranomon Hospital, Tokyo, Japan.
  • Division of Dermatology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

ORCID-Profile: Masatoshi Jinnin, Akiharu Kubo, Shuichi Shimada, Mana Kurimoto-Nishiguchi, Mariko Sakata, Kayo Kunimoto, Yuki Yamamoto

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Jinnin, M., Shimokawa, T., Kishi, A., Hayashi, N., Nagahama, M., Kubo, A., Ozeki, M., Shimada, S., Fukushima, S., Kawabata, T., Okuyama, T., Okubo, A., Sawai, Y., Hayashi, A., Kurimoto-Nishiguchi, M., Sakata, M., Kunimoto, K., & Yamamoto, Y. (2025). Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial. The Journal of Dermatology, 52(5), 872-887. https://doi.org/10.1111/1346-8138.17688

Vancouver

Jinnin M, Shimokawa T, Kishi A, Hayashi N, Nagahama M, Kubo A, et al. Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial. The Journal of Dermatology. 2025;52(5):872-887. doi:10.1111/1346-8138.17688

BibTeX
@article{Jinnin2025,
  author = {Jinnin, Masatoshi and Shimokawa, Toshio and Kishi, Akiko and Hayashi, Nobukazu and Nagahama, Michiko and Kubo, Akiharu and Ozeki, Michio and Shimada, Shuichi and Fukushima, Satoshi and Kawabata, Tomotaka and Okuyama, Tomoki and Okubo, Aki and Sawai, Yumika and Hayashi, Ayato and Kurimoto-Nishiguchi, Mana and Sakata, Mariko and Kunimoto, Kayo and Yamamoto, Yuki},
  title = {Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial},
  journal = {The Journal of Dermatology},
  year = {2025},
  volume = {52},
  number = {5},
  pages = {872--887},
  doi = {10.1111/1346-8138.17688}
}
Kostenlos starten →